Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Mar;139(3):363-71.
doi: 10.1093/jb/mvj037.

Processing of human cathepsin D is independent of its catalytic function and auto-activation: involvement of cathepsins L and B

Affiliations

Processing of human cathepsin D is independent of its catalytic function and auto-activation: involvement of cathepsins L and B

Valérie Laurent-Matha et al. J Biochem. 2006 Mar.

Abstract

The current mechanism proposed for the processing and activation of the 52 kDa lysosomal aspartic protease cathepsin D (cath-D) is a combination of partial auto-activation generating a 51 kDa pseudo-cath-D, followed by enzyme-assisted maturation involving cysteine and/or aspartic proteases and yielding successively a 48 kDa intermediate and then 34 + 14 kDa cath-D mature species. Here we have investigated the in vivo processing of human cath-D in a cath-D-deficient fibroblast cell line in order to determine whether its maturation occurs through already active cath-D and/or other proteases. We demonstrate that cellular cath-D is processed in a manner independent of its catalytic function and that auto-activation is not a required step. Moreover, the cysteine protease inhibitor E-64 partially blocks processing, leading to accumulation of 52-48 kDa cath-D intermediates. Furthermore, two inhibitors, CLICK148 and CA-074Met, specific for the lysosomal cath-L and cath-B cysteine proteases induce accumulation of 48 kDa intermediate cath-D. Finally, maturation of endocytosed pro-cath-D is also independent of its catalytic function and requires cysteine proteases. We therefore conclude that the mechanism of cath-D maturation involves a fully-assisted processing similar to that of pro-renin.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Maturation, glycosylation and activation of human wild-type and D231N mutated human cath-D transfected into cath-D-deficient CD55−/− fibroblasts
(a) Maturation of wild-type and D231N mutated human cath-D. Cells were cultured in DMEM medium with FCS and cell lysates were analyzed by immunoblotting with an antibody specific for human cath-D. (b) Effects of tunicamycin on cellular wild-type and D231N mutated cath-D glycosylation. Cells were either untreated or treated with increasing concentrations of tunicamycin for 24 h and cell lysates were analysed for cath-D expression by Western blotting. (c) Effects of endoglycosidase H on the glycosylation of wild-type and D231N secreted pro-cath-D. Conditioned media from CD55−/−cath-D and CD55−/−D231Ncath-D cells were incubated for different times with or without endoglycosidase H and media were analysed for cath-D expression by Western blotting. (d) Auto-activation of wild-type and D231N secreted pro-cath-D. Conditioned media from CD55−/−cath-D and CD55−/−D231Ncath-D cells were incubated for different times at pH 3.5 in the absence or presence of pepstatin A, and media were analysed for cath-D expression by Western blotting. Black arrows indicate the migration of the 3 forms of wild-type cath-D; grey arrows indicate the migration of the 3 forms of D231Ncath-D; white arrows indicate the migration of non-glycosylated cellular cath-D. K= molecular mass in kDa.
Figure 2
Figure 2. Effects of cysteine protease inhibitors on the maturation of wild-type and D231N mutated cath-D in transfected fibroblasts
(a) Effects of E-64 in fibroblasts. CD55−/−cath-D and CD55−/−D231Ncath-D cells were either untreated or treated for 48 h with 10 mM E-64 and cellular cath-D was analysed by immunoblotting. (b) Concentration dependency of the E-64 effects. CD55−/−cath-D cells were either untreated or treated for 48 h with increasing concentrations of E-64 and cellular cath-D was analysed by immunoblotting. (c) Effects of E-64 using two-dimensional electrophoresis. CD55−/− cath-D cells were either untreated or treated for 48 h with 10 mM E-64 and cellular cath-D was analysed by two-dimensional electrophoresis and immunoblotting. (d) Effects of CA-074Met. CD55−/−cath-D and CD55−/−D231Ncath-D cells were untreated or treated for 48 h with 50 μM CA-074Met and cellular cath-D was analysed by immunoblotting. The effect of 10 mM E-64 is shown. (e) Effects of CLICK-148 alone or in combination with CA-074Met. CD55−/−cath-D and CD55−/−D231Ncath-D cells were either untreated or treated for 48 h with 5 or 20 μM CLICK-148 alone or in combination with 50 μM CA-074Met. Cellular cath-D was analysed by immunoblotting. Brackets indicate the 52-48 kDa processing intermediates detected in CD55−/−cath-D cells and the 51-47 kDa processing intermediates detected in CD55−/−D231Ncath-D cells.
Figure 3
Figure 3. Schematic representation of human cath-D processing
Cath-D is synthesized on the RER as a pre-pro-enzyme that undergoes several proteolytic cleavages during biosynthesis to produce the mature form. Following the initial co-translational removal of the signal peptide to yield 52 kDa pro-cath-D, this pro-enzyme is then processed into numerous 52-48 kDa processing intermediates. These intermediates are not generated by auto-activation, but by the action of unknown proteases whose activities are only partially inhibited by the cysteine protease inhibitor E64, but are not affected by the cath-B or –L inhibitors. The intermediate 48 kDa single-chain species is then cleaved into a mature two-chain enzyme consisting of a light 14 kDa amino-terminal domain and a heavy 34 kDa carboxyl-terminal domain by the cysteine proteases cath-B or cath-L. Accompanying this conversion to the two-chain species, 7 amino acid residues between the 14 KDa light and 34 kDa heavy chains are removed [15]. Several more amino acids are removed from the carboxyl terminus of the 34 kDa heavy chain [16].
Figure 4
Figure 4. Processing of endocytosed wild-type and D231N mutated human cath-D
(a) Processing of endocytosed human D231Npro-cath-D. Parental cath-D-deficient CD55−/− fibroblasts were incubated for 18 h with 35S-labelled conditioned medium containing the secreted wild-type or D231N pro-cath-D. After washing, cell lysates containing endocytosed [S35]methionine-labelled cath-D were analyzed by SDS-PAGE after immunoprecipitation. Immunoprecipitation was performed in triplicate. (b) Effects of E-64. CD55−/− fibroblasts were incubated for 18 h with 35S-labelled conditioned medium containing the wild-type pro-cath-D in the absence or presence of 10 mM E-64. Endocytosed [S35]methionine-labelled cath-D was analyzed by SDS-PAGE, as described in panel a. (c) Effects of CA-074Met. CD55−/− fibroblasts were incubated for 18 h with 35S-labelled conditioned medium containing pro-cath-D in the absence or presence of 25 μM CA-074Met. Endocytosed [S35]methionine-labelled cath-D was analyzed by SDS-PAGE. (d) Effects of CLICK-148 alone or in combination with CA-074Met. CD55−/− fibroblasts were incubated for 18 h with the 35S-labelled conditioned medium containing pro-cath-D in the absence or presence of 20 μM CLICK-148 alone or in combination with 25 μM CA-074Met. Endocytosed [S35]methionine-labelled cath-D was analyzed by SDS-PAGE.

Similar articles

Cited by

References

    1. Tang J, Wong RN. Evolution in the structure and function of aspartic proteases. J Cell Biochem. 1987;33:53–63. - PubMed
    1. Hsueh WA, Baxter JD. Human prorenin. Hypertension. 1991;17:469–477. - PubMed
    1. Richo G, Conner GE. Proteolytic activation of human procathepsin D. Adv Exp Med Biol. 1991;306:289–296. - PubMed
    1. Conner GE, Richo G. Isolation and characterization of a stable activation intermediate of the lysosomal aspartyl protease cathepsin D. Biochem. 1992;31:1142–1147. - PubMed
    1. Larsen LB, Boisen A, Petersen TE. Procathepsin D cannot autoactivate to cathepsin D at acid pH. FEBS Lett. 1993;319:54–58. - PubMed

Publication types